Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glucagon-Like Peptide-1 Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT07223216
What this trial is testing

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Who this might be right for
Obesity
Biomea Fusion Inc. 80
Testing effectiveness (Phase 2)Study completedNCT04687514
What this trial is testing

Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

Who this might be right for
Sexual Functioning
University Hospital, Basel, Switzerland 26
Large-scale testing (Phase 3)Ended earlyNCT03419624
What this trial is testing

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Who this might be right for
ObesityDiabetes Mellitus, Type 2
Universitätsklinikum Hamburg-Eppendorf 13
Testing effectiveness (Phase 2)Looking for participantsNCT07685808
What this trial is testing

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Who this might be right for
Overweight or Obesity
Regeneron Pharmaceuticals 360
Testing effectiveness (Phase 2)Study completedNCT02838589
What this trial is testing

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

Who this might be right for
Stroke
Christina Kruuse 30
Not applicableNot Yet RecruitingNCT07567378
What this trial is testing

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

Who this might be right for
Psoriatic ArthritisOsteoarthitisKnee+12 more
JULIO GRANADOS MONTIEL 30
Testing effectiveness (Phase 2)Study completedNCT06703021
What this trial is testing

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Who this might be right for
ObesityOverweightChronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 85
Large-scale testing (Phase 3)Study completedNCT00866658
What this trial is testing

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Who this might be right for
Diabetes Mellitus, Type 2
Sanofi 311
Not applicableNot Yet RecruitingNCT07605390
What this trial is testing

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Who this might be right for
Chronic Kidney DiseaseType 2 Diabetes
Baylor Research Institute 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07642635
What this trial is testing

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Who this might be right for
Duchenne Muscular Dystrophy (DMD)
Vanderbilt University Medical Center 30
Large-scale testing (Phase 3)Study completedNCT03767543
What this trial is testing

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Who this might be right for
Type 2 Diabetes Mellitus
Sanofi 265
Not applicableStudy completedNCT03590626
What this trial is testing

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Who this might be right for
Non Alcoholic Fatty Liver DiseaseType2 Diabetes Mellitus
Medanta, The Medicity, India 60
Not applicableLooking for participantsNCT07732426
What this trial is testing

Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

Who this might be right for
Food Addiction TendencyObesityOverweight
Seoul National University Hospital 30
Early research (Phase 1)Study completedNCT04347252
What this trial is testing

Glucagon Regulation of Glucose Metabolism

Who this might be right for
Insulin Secretion
David D'Alessio, M.D. 19
Not applicableUnknownNCT05779644
What this trial is testing

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Who this might be right for
MetforminObesity, AbdominalDiabetes Mellitus, Type 2+4 more
RenJi Hospital 300
Not applicableStudy completedNCT01825148
What this trial is testing

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

Who this might be right for
Type 1 Diabetes
Radboud University Medical Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT07169942
What this trial is testing

Aleniglipron Phase 2 Body Composition Study

Who this might be right for
Obesity, Overweight, or Chronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 71
Testing effectiveness (Phase 2)Ended earlyNCT06515418
What this trial is testing

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Who this might be right for
Obesity
BioAge Labs, Inc. 204
Not applicableNot Yet RecruitingNCT07611552
What this trial is testing

Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Who this might be right for
Obesity & Overweight
Huazhong University of Science and Technology 600
Not applicableEnded earlyNCT01303315
What this trial is testing

TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

Who this might be right for
Diabetes Mellitus, Type 2
MetaCure (USA), Inc. 20
Next Page